Get started
Catalent, Inc.Catalent, Inc.Catalent, Inc.

Catalent, Inc.

No trades
Buy CTLT
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

CTLT trade ideas

CTLT Anticipates Boost From Demand for Injectable Weight-LossMain Highlights 1. Syringe maker Catalent suggested soaring demand for injectable weight-loss drugs could lead to sizable revenue gains, and shares surged. 2. The company said sales of its pre-filled syringes could increase more than five-fold because of the popularity of those drugs. 3. Catalent also released preliminary quarterly results, and revenue exceeded forecasts. Syringe maker Catalent (NYSE: CTLT) said soaring demand for injectable weight-loss drugs could lead to big revenue gains, and shares surged over 11%. The company indicated that it expected a majority of its current and upcoming production capacity for pre-filled syringes until fiscal year 2026 to soon be booked out. Catalent syringes are used to deliver Novo Nordisk’s (NVO) Wegovy, a diabetes treatment that has been shown to help patients lose weight. Wegovy is in the class of drugs known as GLP-1, which also includes Novo Nordisk’s Ozempic and Eli Lilly’s (LLY) Mounjaro and Zepbound. Catalent also reported preliminary first quarter fiscal 2024 revenue of $982 million, down 4% from a year ago but more than analysts’ estimates. The company announced on Monday it was delaying release of its quarterly statement because of a $700 million goodwill impairment charge Technical Analysis (NYSE: CTLT) is trading near the bottom of its 52-week range and below its 200-day simple moving average. What does this mean? Investors have been pushing the share price lower, and the stock still appears to have downward momentum.
NYSE:CTLTLong
by DEXWireNews
Catalent about to close it's gap?Catalent - 30d expiry - We look to Sell a break of 65.98 (stop at 69.98) We have a Gap open at 6.2. from 56.05 to 69.46. The primary trend remains bearish. A break of support at 66.44 should lead to a more aggressive move lower towards 55.00. This stock has seen poor sales growth. Our outlook is bearish. Our profit targets will be 55.98 and 53.98 Resistance: 70.00 / 72.54 / 76.50 Support: 66.44 / 55.00 / 52.00 Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Signal Centre’). Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Signal Centre.
NYSE:CTLTShort
by VantageMarkets
CTLT: Bottoming out?Catalent Short Term - We look to Buy at 63.84 (stop at 56.95) The primary trend remains bearish. Bespoke support is located at 63.30. Support could prove difficult to breakdown. We look for a temporary move lower. Preferred trade is to buy on dips. Our profit targets will be 82.27 and 88.00 Resistance: 82.50 / 100.00 / 120.00 Support: 63.30 / 48.00 / 30.00 Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Signal Centre’ ). Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Signal Centre.
NYSE:CTLTLong
by VantageMarkets
Catalent Is about to beat earnings?Now I've been watching Catalent, since they partnered up with one of the stocks I hold for a COVID treatment. Novan. Doing a quick glance at CTLT I noticed a TA pattern known as a double bottom and with certain catalyst coming out, maybe its about to run up and leave this bearish trend. News -ER is in 14 days -They have partnered up with Novan to design the injection of Novan's product that can treat/reduce spread of COVID by 90%, which comes out in Q3. TA As you can see the curve lines represents the two bottoms and the top with two white lines pointing at support points. Now note that this could be just a trading zone, yet we will get into the bullish argument. -MACD a cross over is turning bullish -RSI is rising, yet would need to break 52.47. Also if you want, you could say its already bullish on the RSI with a small error margin in TA. -Resistance would be at 110.87, 114.67, and finally the high of 125-127 -Support is at 106.89 and 100.52. -The emas aren't bad with it ending on top of the 50ema which leans bullish in the short term. -VPVR levels are really high at where it closes today with the resistance in the VPVR at 113 and the support at 106-107 Final thoughts It leans bullish if the Double Bottom pattarn plays out and could see it run up nicely on ER. This ER is Q2 for Catalant, so the COVID play will come out sometime after.
NYSE:CTLTLong
by nathanielx9
Catalent Is Attempting to Turn Higher After a PullbackCatalent is an interesting company because it managed to get added to the S&P 500 before Tesla in early September. It also traces its history back to the creation of soft-gel pills in the early 1930s. CTLT has trended higher most of the year, fueled by strong results. The stock rallied after its last earnings report on November 3, and has now retraced most of that move. The pullback has brought the shares back to the $95 area where they peaked in October and the 50-day simple moving average. It also dragged stochastics down to an oversold condition, but they're now rebounding. Market sentiment may favor CTLT because biotechnology stocks have gained strength in the last two weeks. There are additionally signs that the “reopening trade” (energy/industrials/financials) is getting tired – especially as Covid cases rebound. That could make investors more interested in a non-cyclical healthcare play like CTLT. TradeStation is a pioneer in the trading industry, providing access to stocks, options, futures and cryptocurrencies. See our Overview for more.
NYSE:CTLTLong
by TradeStation
1
BREAKOUT CUP WITH HANDLE AND HIGH VOLUM BUY CTLT ABOUT 93.66$Catalent (CTLT) has contracts to make three of the leading Covid-19 vaccine candidates. In the company's June-quarter earnings release early Monday, CEO John Chiminski said a shift to more innovative technologies is "reflected in more than 50 Covid-19-related program wins." Among other gains, Chiminski said Catalent has built its cash position to more than $950 million, "positioning us to continue our growth investments." OPERATING INCOME 11% ABOUT 1% CAPITAL
NYSE:CTLTLong
by Benji-13